血清miR-9-5p miR-576-5p水平在子宫内膜癌中的表达及临床意义  

Expression of Serum miR-9-5p and miR-576-5p in Patients with Endometrial Cancer and the Clinical Significances

作　　者：杜林 杜晓艳[1] DU Lin;DU Xiaoyan(The First Hospital of Harbin,Heilongjiang Harbin 150026,China)

机构地区：[1]黑龙江省哈尔滨市第一医院妇产科,黑龙江哈尔滨150026

出　　处：《河北医学》2025年第3期415-420,共6页Hebei Medicine

基　　金：黑龙江省哈尔滨市应用技术研究与开发项目,(编号:2017RAQXJ193,2017AB9BS041)。

摘　　要：目的:探讨子宫内膜癌患者血清miR-9-5p,miR-576-5p表达与临床病理特征以及预后的关系。方法:招募2018年1月至2021年1月我院收治的98例子宫内膜癌患者(子宫内膜癌组)和同期72例于妇产科体检的健康女性(对照组)。采集外周静脉血,应用实时荧光定量聚合酶链反应(RT-PCR)检测血清miR-9-5p,miR-576-5p表达,比较不同病理特征患者血清miR-9-5p,miR-576-5p表达差异。出院后定期随访,统计3年总生存(OS)情况。结果:子宫内膜癌组血清miR-9-5p表达低于对照组(0.86±0.21 vs 2.55±0.93,t=-17.412,P<0.05),miR-576-5p表达高于对照组(3.42±1.16 vs 1.57±0.45,t=12.833,P<0.05)。FIGO分期Ⅲ~Ⅳ期、低分化、深层肌层浸润、淋巴结转移、远处转移子宫内膜癌患者血清miR-9-5p表达低于FIGO分期Ⅰ~Ⅱ期、中高分化、浅层肌层浸润、无淋巴结转移、无远处转移患者(P<0.05),miR-576-5p表达高于FIGO分期Ⅰ~Ⅱ期、中高分化、浅层肌层浸润、无淋巴结转移、无远处转移患者(P<0.05)。随访3年,2例失访,死亡36例,存活60例。miR-9-5p低表达子宫内膜癌患者3年OS率低于miR-9-5p高表达子宫内膜癌患者(P<0.05),miR-576-5p高表达子宫内膜癌患者3年OS率低于miR-576-5p低表达子宫内膜癌患者(P<0.05)。淋巴结转移、远处转移、高miR-576-5p是子宫内膜癌死亡的危险因素[HR(95%CI):1.921(1.179~3.130)、2.050(1.121~3.750)、1.683(1.162~2.439),P<0.05],miR-9-5p高表达是保护因素[HR(95%CI):0.670(0.497~0.905),P<0.05]。结论:子宫内膜癌患者血清miR-9-5p表达下调,miR-576-5p表达上调,且与恶性病理特征、不良预后有关。Objective:To investigate the relationship between expression of serum miR-9-5p and miR-576-5p with clinicopathological features and prognosis in patients with endometrial cancer.Methods:A total of 98 patients with endometrial cancer admitted to the department of obstetrics and gynecology of our hospital from January 2018 to January 2021(endometrial cancer group)and 72 healthy women who underwent physical examination in the department of obstetrics and gynecology during the same period(control group)were recruited.Peripheral venous blood was collected,and the expressions of miR-9-5p and miR-576-5p in serum were detected by real-time fluorescent quantitative polymerase chain reaction(RT-PCR),and the differences in expressions of serum miR-9-5p and miR-576-5p of patients with different pathological characteristics were compared.The 3-year overall survival(OS)was measured by regular follow-up after discharge.Results:The expression of miR-9-5p in endometrial carcinoma group was significantly lower than that in control group(0.86±0.21 vs 2.55±0.93,t=-17.412,P<0.05),and the expression of miR-576-5p was significantly higher than that of control group(3.42±1.16 vs 1.57±0.45,t=12.833,P<0.05).Significantly lower serum miR-9-5p expression and higher miR-576-5p were detected in endometrial cancer patients with the International Federation of Gynecology and Obstetrics(FIGO)stagesⅢ-Ⅳ,low differentiation,deep muscle infiltration,lymph node metastasis,and distant metastasis compared to those with FIGO stagesⅠ~Ⅱ,medium-highly differentiation,shallow muscle infiltration,no lymph node metastasis,and no distant metastasis(all P<0.05).After 3 years of follow-up,2 cases were lost to follow-up,36 died and 60 survived.The 3-year OS rate of endometrial cancer patients with low expression of miR-9-5p was significantly lower than that of endometrial cancer patients with high expression of miR-9-5p(P<0.05);the 3-year OS rate of endometrial cancer patients with high expression of miR-576-5p was significantly lower than that of end

关 键 词：子宫内膜癌 临床病理特征 预后 miR-9-5p miR-576-5p 

分 类 号：R73[医药卫生—肿瘤]